Oral bisphosphonate compliance and persistence: a matter of choice?
- PMID: 20458571
- PMCID: PMC3017316
- DOI: 10.1007/s00198-010-1274-6
Oral bisphosphonate compliance and persistence: a matter of choice?
Abstract
Compliance to oral bisphosphonates is suboptimal, with negative consequences of increased healthcare utilization and less effective fracture risk reduction. Extending dose interval increased adherence only moderately. We used literature derived from multiple chronic conditions to examine the problem of noncompliance with osteoporosis medication. We reviewed the literature on adherence to osteoporosis medication as well as that across multiple chronic conditions to understand what is known about the cause of the poor adherence. Poor compliance to oral medications is due mostly, not to forgetfulness, but to deliberate choice. Gender differences and style of healthcare management also play a role. Preliminary data suggest psychobehavioral interventions may help to improve motivation. We need to understand better reasons for poor compliance before effective interventions can be developed. Forgetfulness is only a small part of poor compliance. Patient preferences must be considered in medication decision making.
Similar articles
-
Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.Osteoporos Int. 2013 Oct;24(10):2639-47. doi: 10.1007/s00198-013-2365-y. Epub 2013 Apr 20. Osteoporos Int. 2013. PMID: 23604250
-
GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.Osteoporos Int. 2012 Jan;23(1):223-31. doi: 10.1007/s00198-011-1535-z. Epub 2011 Feb 10. Osteoporos Int. 2012. PMID: 21308365
-
Adherence to osteoporosis medications amongst Singaporean patients.Osteoporos Int. 2012 Mar;23(3):1053-60. doi: 10.1007/s00198-011-1635-9. Epub 2011 Apr 19. Osteoporos Int. 2012. PMID: 21503813
-
[Innovation of bisphosphonates for improvement of adherence.].Clin Calcium. 2017;27(2):197-202. Clin Calcium. 2017. PMID: 28123121 Review. Japanese.
-
Improving compliance and persistence with bisphosphonate therapy for osteoporosis.Am J Med. 2006 Apr;119(4 Suppl 1):S18-24. doi: 10.1016/j.amjmed.2005.12.019. Am J Med. 2006. PMID: 16563937 Review.
Cited by
-
Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA.Arch Osteoporos. 2015;10:231. doi: 10.1007/s11657-015-0231-6. Epub 2015 Aug 22. Arch Osteoporos. 2015. PMID: 26297076 Free PMC article.
-
Prescribing Physical Activity for the Prevention and Treatment of Osteoporosis in Older Adults.Healthcare (Basel). 2017 Nov 6;5(4):85. doi: 10.3390/healthcare5040085. Healthcare (Basel). 2017. PMID: 29113119 Free PMC article. Review.
-
A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.Osteoporos Int. 2012 Apr;23(4):1415-24. doi: 10.1007/s00198-011-1729-4. Epub 2011 Jul 23. Osteoporos Int. 2012. PMID: 21786005
-
Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions.Ther Adv Musculoskelet Dis. 2013 Aug;5(4):182-98. doi: 10.1177/1759720X13485829. Ther Adv Musculoskelet Dis. 2013. PMID: 23904863 Free PMC article.
-
Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis.J Bone Miner Metab. 2021 Sep;39(5):824-832. doi: 10.1007/s00774-021-01221-6. Epub 2021 Apr 5. J Bone Miner Metab. 2021. PMID: 33821302 Free PMC article.
References
-
- Silverman SL, Cramer JA, Sunyecz JA, et al (2007) Women are more persistent with monthly bisphosphonate therapy compared to weekly bisphosphonates: 12 month results from two retrospective databases. Presented at ASBMR Montreal, 19 Sept 2007. Abstract W366